Lemetayer Julie, Blois Shauna
Department of Clinical Studies, Ontario Veterinary College, University of Guelph, Guelph, Ontario N1C 1G9.
Can Vet J. 2018 Apr;59(4):397-407.
Many articles published in the past few years have contributed to a better understanding of the use of trilostane in dogs. Trilostane is a competitive inhibitor of 3β-hydroxysteroid dehydrogenase, the enzyme essential for synthesis of cortisol and all other steroids. Trilostane is reported to be safe and effective in the treatment of pituitary-dependent hyperadrenocorticism (HAC), adrenal-dependent HAC, and alopecia X. While trilostane controls most of the clinical signs associated with HAC, abnormalities such as hypertension, hypercoagulability, and proteinuria may persist despite therapy. Because the duration of cortisol suppression after a dose of trilostane is often less than 12 hours, many dogs with HAC could benefit from low dose trilostane treatment every 12 hours. Many controversies regarding trilostane still exist. This review provides a comprehensive commentary on trilostane's indications, mode of action, dose, monitoring, efficacy, and adverse effects.
在过去几年发表的许多文章有助于更好地理解曲洛司坦在犬类中的应用。曲洛司坦是3β-羟基类固醇脱氢酶的竞争性抑制剂,该酶是皮质醇和所有其他类固醇合成所必需的。据报道,曲洛司坦在治疗垂体依赖性肾上腺皮质功能亢进症(HAC)、肾上腺依赖性HAC和脱毛X方面是安全有效的。虽然曲洛司坦可控制大多数与HAC相关的临床症状,但尽管进行了治疗,高血压、高凝性和蛋白尿等异常情况可能仍然存在。由于一剂曲洛司坦后皮质醇抑制的持续时间通常少于12小时,许多患有HAC的犬可能受益于每12小时一次的低剂量曲洛司坦治疗。关于曲洛司坦仍存在许多争议。本综述对曲洛司坦的适应症、作用方式、剂量、监测、疗效和不良反应进行了全面的评论。